Deadline nears to file claim in class-action lawsuit over drug Rexulti
ShareSave for laterPlease log in to bookmark this story.Log InCreate Free AccountThe deadline is fast approaching for Canadians to claim their share of a multimillion-dollar class-action lawsuit over the drug Rexulti.Canadians have until Aug. Applicants could receive anywhere from roughly $6,500 for mild cases to more than $102,000 in more severe cases.
- ▪ShareSave for laterPlease log in to bookmark this story.Log InCreate Free AccountThe deadline is fast approaching for Canadians to claim their share of a multimillion-dollar class-action lawsuit over the drug Rexulti.Canadians have until Au
- ▪Applicants could receive anywhere from roughly $6,500 for mild cases to more than $102,000 in more severe cases.
The Globe and Mail publishes from Canada and files mainly under world. We currently carry 1,868 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Globe and Mail |
| Canonical URL | https://www.theglobeandmail.com/canada/article-class-action-lawsuit-drug-rexulti/ |
| Publication time | Mon, 27 Jul 2026 10:44:50 +0000 |
| Retrieval time | 2026-07-27T10:51:12.858Z |
| Last seen | 2026-07-27T10:51:12.858Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | Pg47l7929x2s · 1 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
ShareSave for laterPlease log in to bookmark this story.Log InCreate Free AccountThe deadline is fast approaching for Canadians to claim their share of a multimillion-dollar class-action lawsuit over the drug Rexulti.Canadians have until Aug. 27 to file a claim for their share of a $4.75-million settlement over the antipsychotic medication used to treat schizophrenia and depression.Quebec Superior Court approved the settlement in November, one year after authorizing the national class action against Otsuka Canada Pharmaceutical Inc.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Globe and Mail.
Discussion
0 commentsMore from The Globe and Mail
